A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1

Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2017
This article has no abstract
Epistemonikos ID: 25ee728315fcfcf7ea352ac289e918627af88c41
First added on: Apr 16, 2025